NYC Councilman Paul Vallone credits Hydroxychloroquine for COVID-19 recovery – A Democratic New York City Councilman says hydroxychloroquine saved his life after a near-fatal run-in with COVID-19 in March. Paul Vallone, who represents northeast Queens, took the drug along with a standard flu Z-pack, and came back from the brink almost immediately.
“I couldn’t breathe, very weak, couldn’t get out of bed. My doctor prescribed it. My pharmacy had it. Took it that day and within two to three days I was able to breathe,” Vallone told The Post. “Within a week I was back on my feet.”
Though Vallone went public with his coronavirus diagnosis in an April 1 Twitter post, saying he was experiencing “mild symptoms,” his actual condition was considerably more severe. Vallone’s initial prognosis was particularly grim, as he also suffers from sarcoidosis, an auto-immune disease that attacks his lungs.
“We were in panic mode when I went down because I didn’t have a lot of immune response,” he said. “I needed something to stay alive.”
Hydroxychloroquine “worked for me.”
HOUSTON – Houston Methodist Hospital is making national headlines after doctors used a new drug to help treat critically ill COVID-19 patients.
Methodist was the first to report the rapid recovery of patients on ventilators and those with severe medical conditions after three days of treatment. The drug is called RLF-100 and is also known as aviptadil. It has been approved by the FDA for emergency use at multiple clinical sites in patients who are too ill to enter the FDA’s Phase 2/3 trials.
According to a press release from the drug maker NeuroRX, independent researchers have reported that aviptadil blocked replication of the SARS coronavirus in human lung cells and monocytes.
The number of doctors publicly supporting the use of hydroxychloroquine for early treatment or prevention is growing.
Recently, Dr. Kevin R. Wheelan, chief of cardiology at Baylor Heart and Vascular Hospital in Dallas and Dr. Peter McCullough, a clinical cardiologist and professor at the Texas A&M School of Medicine, issued a letter supporting the emergency use authorization (EUA) of hydroxychloroquine for outpatient treatment and prophylaxis for COVID-19.
The letter dated July 6 was submitted in support of a petition by several other doctors asking the Federal Drug Administration (FDA) to reissue an emergency use authorization for hydroxychloroquine that has been donated to the national stockpile.
Wheelan and McCullough say in their letter that “when started earlier in the hospital course…and in outpatients, antimalarials [hydroxychloroquine] may reduce the progression of disease, prevent hospitalizations, and are associated with reduced mortality.” They cite several studies for support.